

REMARKS

Applicants respectfully request that the Examiner enter the forgoing amendment to the written description. Applicants herein correct the citation to the Gruenberg reference [0003]. In addition, Applicants remove reference to a non-functioning web site [0004] as well as clarify the full chemical name for sPLA butyrate [0020]. Further, at the Examiner's request Applicants have modified FIG 6 [0019] [0089] to be more clear by including labels for (61) and (62) as well as including the corresponding labels for Figures 6a-c, respectively. Accordingly, the above amendments contain no new matter. Applicants respectfully request that the Examiner enter the forgoing amendment to the written description.

Applicants have reviewed the references being submitted concurrently with this paper and the payment of the issue fee. The references relate to general information regarding the detection of pathogens associated with urinary tract infections and provide background information. It is the belief of all associated with the filing and prosecution of this patent application that these references are not material to the patentability of the claims as currently allowed. For example, the Gruenberg and Voss references describe the pathogens that are known to be associated with urinary tract infections, they do not disclose any methods for rapid detection of such infections. Further, the Cooke and Miles references describe various chromogens that are known in the art for use in the detection of pathogens. U.S. Patent No. 5,221,606 to Richardson et al. was considered by the Examiner during the prosecution of the application. Additionally, EP 0841403 was identified in the International Search Report as referring to the general state of the art and not of particular relevance to the claimed invention. Finally, the Written Opinion of the International Searching Authority determined that all pending claims were both novel and inventive over the closest existing prior art. For all of the foregoing


reasons, Applicants believe that the references submitted concurrently herewith under 37 C.F.R. § 1.97(h)(i) are not material to the patentability of any allowed claims and Applicants request that they simply be placed in the file.

Because this amendment is being concurrent with the payment of the issue fee, Applicants believe that no fee or petition for this amendment is necessary. However, should a fee be deemed to be necessary, the Commissioner is hereby authorized to charge any fees required by this action or any future action to Deposit Account No. 16-1435.

Should the Examiner have any questions relating to the instant application, the Examiner is invited to telephone the undersigned at (336) 607-7442 to discuss any issues.

Respectfully submitted,

Date: 19 January 2010



Leslie T. Grab (Reg. No. 62,067)

KILPATRICK STOCKTON LLP

1001 West Fourth Street
Winston-Salem, North Carolina 27101-2400
Phone: (336) 607-7442
Facsimile: (336) 607-7500